Payment overview · 2025
General Payments
$243.91
10 reported records · 9 companies
Healthcare provider profile · identity verified
Steven Webster, DO
Allopathic & Osteopathic Physicians|Family Medicine · POCATELLO, ID · NPI 1922592617
Verified facts
What the public records show
CMS Open Payments records show Steven Webster, DO received $243.91 in general payments during 2025 across 10 reported records.
Xeris Pharmaceuticals, Inc. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.53 | 27.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.47 | 13.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.85 | 13.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.02 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.75 | 8.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.02 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.56 | 6.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.68 | 6.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.03 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.91 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $66.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 67 |
| Omeprazole | Omeprazole | 200 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 57 |
| Metformin Hcl Er | Metformin Hcl | 141 | 48 |
| Lisinopril | Lisinopril | 130 | 42 |
| Gabapentin | Gabapentin | 125 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 37 |
| Losartan Potassium | Losartan Potassium | 105 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 32 |
| Famotidine | Famotidine | 94 | 30 |
| Trazodone Hcl | Trazodone Hcl | 85 | 35 |
| Ozempic | Semaglutide | 84 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 31 |
| Potassium Chloride | Potassium Chloride | 76 | 22 |
| Furosemide | Furosemide | 75 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 22 |
| Mounjaro | Tirzepatide | 72 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 15 |
| Metformin Hcl | Metformin Hcl | 70 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 20 |
| Allopurinol | Allopurinol | 66 | 23 |
| Estradiol | Estradiol | 65 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 24 |
| Glimepiride | Glimepiride | 59 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 20 |
| Tramadol Hcl | Tramadol Hcl | 53 | 22 |
| Jardiance | Empagliflozin | 52 | 18 |
| Meloxicam | Meloxicam | 51 | 25 |
| Simvastatin | Simvastatin | 49 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 44 | 13 |
| Carvedilol | Carvedilol | 43 | 16 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Eliquis | Apixaban | 41 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Spironolactone | Spironolactone | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 18 |
| Montelukast Sodium | Montelukast Sodium | 38 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 12 |
| Fluconazole | Fluconazole | 34 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 13 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Topiramate | Topiramate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Progesterone | Progesterone, Micronized | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Diazepam | Diazepam | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.91 · 10 records | Xeris Pharmaceuticals, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, General - Pain Management, INSPIRE, OTEZLA, Ozempic, RECORLEV, REPATHA, Symbravo, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error